PredMart › Blog › Culture › Next James Bond Actor 2026 Odds & Analysis

Culture · · 12 min read · By

Next James Bond Actor 2026 Odds & Analysis

Next James Bond actor odds have Jack Lowden in front at 37.8% as of October 2026, with "No Bond chosen" (no official announcement by December 31, 2026) second at 24.4% and Callum Turner third at 13.3%. Everyone else on a board of two dozen outcomes trades below 5%. The headline number hides the more useful signal: Lowden is the favourite, but he is well off the roughly 49% he hit in early September, while the "no announcement this year" contract has quietly climbed back to a quarter of the market. On PredMart you can take a leveraged long position on any single outcome here, from Lowden to the "No Bond chosen" contract itself.

This is a casting market with an unusual shape. There is no vote, no poll and no box office to model. The price moves on leaks, trade reporting, offhand remarks by actors and the absence of news, and it resolves on a single official announcement from Amazon MGM Studios. That makes the question "who" inseparable from the question "when", and the 24.4% sitting on "No Bond chosen" is the market saying the timing is still very much in doubt.

How this market resolves

The contract on each actor resolves Yes if that actor is officially announced as the next James Bond by December 31, 2026, 11:59 PM ET. It resolves on the first official announcement, regardless of any later changes. If no actor is announced in that window, the market resolves to "No Bond chosen". The primary resolution source is official information from Amazon MGM Studios, though a consensus of credible reporting can also be used.

Two practical consequences follow. First, every actor contract is really a two-part bet: that this person gets the role, and that the studio says so before the year is out. Second, a credible leak that hardens into consensus could, in principle, move the board before any press release, which is why individual reports have produced such sharp swings in this market.

The backdrop is well documented. Amazon MGM Studios announced in June 2025 that Denis Villeneuve would direct the next Bond film, with Amy Pascal and David Heyman producing and Steven Knight, the creator of Peaky Blinders and SAS: Rogue Heroes, writing the screenplay. Casting director Nina Gold is running the search. In May 2026 the studio said in a statement that "the search for the next James Bond is underway" and that it did not plan to comment on specific details during casting. Production is widely reported to be targeted for 2027, and no release date has been announced.

Front-runner: Jack Lowden at 37.8%

Lowden, the Scottish actor best known as River Cartwright in Slow Horses, was a fringe name for most of the spring. In mid-June his contract traded around 6%. Two separate pieces of talk turned him into the favourite.

The first came in mid-August (coverage began on August 12), when Richard Osman said on his podcast The Rest Is Entertainment that someone had told him "for definite" who the new Bond was, adding "the name I've heard is Jack Lowden." Osman was careful to say it was "definitely not a 'he's definitely got it' thing," only that Lowden was "definitely being strongly considered," and coverage at the time stressed that it was unclear who his source was. Lowden's price climbed into the mid-20s.

The second was bigger. In early September, while promoting the new season of Slow Horses on Canadian television, Gary Oldman, Lowden's co-star, said in remarks widely relayed by Deadline: "They have picked him. They have made their choice, but they have not announced it yet." Oldman said he hoped it was Lowden. Newsweek reported on September 8 that Lowden had jumped to 49% in prediction markets, with "No Bond chosen" around 16% and Jack Barton near 12%. Daily price data shows Lowden printing about 49.5% on September 9, his high for the market so far.

Then the walk-back. In follow-up comments reported by Deadline, Oldman clarified that he did not actually know who had been cast and was simply hoping it was Lowden, and Steven Knight told BBC Radio 4 that he could not speak about the subject. Lowden's price fell back toward the low 30s, then spent late September swinging on thin, noisy prints between roughly 32% and 48% before settling. As of October 2026 it sits at 37.8%, with the order book tight around that level (a best bid of 37.7% against a best ask of 37.8%). In early October, Saoirse Ronan, Lowden's wife, also batted back the rumours when asked about them.

The honest reading is that Lowden's premium rests on two pieces of secondhand talk, neither of which claims firsthand knowledge of a decision. What keeps him on top is that nothing has knocked him off: no credible report has tied any rival more firmly to the role since September. That is a real but fragile foundation. A 37.8% price implies the market sees him as roughly a coin flip to be the eventual choice if an announcement comes this year, because roughly a quarter of the probability is parked on "no announcement" at all. Stripping out "No Bond chosen", Lowden's share of the remaining probability is about 50%.

Biggest mover: Callum Turner's long slide, and the round trip in Lowden

By total distance travelled, Lowden is the biggest mover on the board: from about 6% in June to 49.5% in September and back to 37.8% now. The catalyst trail is clean, with the Osman podcast in mid-August and the Oldman interview in early September doing almost all of the work.

Callum Turner's chart tells the opposite story, and it is arguably more informative. Turner was the bookmakers' favourite going into 2026. Bookmakers had him as the clear favourite in late 2025, and a January tabloid report claiming he had already been confirmed came to nothing. When this market opened in May, Turner climbed above 50% at the turn of June and held in the 30s through most of July.

He then lost the lead in August. No new reporting firmed up his candidacy, and the August rumour cycle ran almost entirely in favour of other actors, first Lowden and then Jack Barton. Turner fell to around 15% by mid-August and below 9% around the Oldman headlines. Since then his contract has been the most volatile of the main names, swinging between roughly 7% and 31% on daily prints without any obvious single news item, and it sits at 13.3% now with a wide spread (11.5% bid, 15.0% ask).

That volatility is the leverage-relevant feature of this board. A return from 13.3% to the 22.9% Turner printed in the first week of October would be roughly a 70% gain on the position, or nearly 300% on margin at 4x before costs, but the same mechanics cut the other way: at 4x, a fall of only about 6% in the position's marked value would hit the 20% maintenance line, which is narrower than Turner's current bid-ask spread.

The rest of the field

"No Bond chosen" at 24.4%. This is the second-most likely single outcome and arguably the most underappreciated. It has been remarkably stable, mostly sitting between about 19% and 28% since mid-August despite a few one-day spikes, which suggests traders have a settled view that a missed deadline is well short of a coin flip but far from negligible. The case for it is straightforward. Producer Amy Pascal said in early August that she expected a new 007 to be named by the end of the year, which is a target, not a commitment. Amazon MGM film chief Courtenay Valenti had already urged patience at CinemaCon in April. And on September 4, Puck's Matt Belloni reported, as relayed by Cosmic Book News, that test deals were going out to contenders, that the shortlists circulating online were unreliable, and that screen tests would not happen until later in the fall. If screen tests are still being scheduled in autumn, an announcement by December 31 requires a fairly quick turnaround. Against that, the producers have consistently pointed to year-end, and studios often prefer to name a new lead well ahead of a shoot, which is reported for 2027. October 5, Global James Bond Day, came and went without a casting announcement, and after dipping to about 19% in the days that followed, the contract has climbed back to 24.4%.

Jack Barton at 4.7%. Barton is the clearest example of a rumour that lifted a price and then faded. On August 26, Page Six reported that Villeneuve and Nina Gold had searched the UK for unknowns and that Barton, best known for Heartstopper and also seen in SAS: Rogue Heroes and Poor Things, had come out on top. PinkNews and Film Stories picked it up, and Newsweek had him near 12% on September 8. The SAS: Rogue Heroes link to Steven Knight was noted by several commentators. But the Belloni report and the Lowden momentum drained the bid, and Barton is down about 7.5 points over the past month. At 4.7% he is priced as a credible outsider, not a contender.

Josh O'Connor at 3.5%. O'Connor opened as one of the names in the 20s back in May but drifted to well under 1% by September. He jumped back to 3.5% in the past day, after reporting on October 10 described a sharp single-day swing in his contract on another exchange that could not be tied to any new casting report. The book is thin (1.1% bid, 5.9% ask), so the displayed price says more about one or two orders than about new information.

Jack O'Connell at 3.4%. O'Connell has stayed in the conversation since ScreenRant's September roundup reported he was still in contention, but no recent report has singled him out, and his contract has bounced between under 1% and about 11% without a clear catalyst.

Tom Francis at 3.3%. Francis has the most concrete reporting of any outsider. In May 2026, Variety reported, citing a source with knowledge of the search, that the Olivier Award-winning Sunset Boulevard star had auditioned, with representatives for Francis and Amazon MGM declining to comment. His screen credits are limited, which fits the reported preference for a relatively fresh face but also makes him a harder sell for a franchise lead. He has not been named in the main shortlist reports since.

Jacob Elordi (2.2%), Paul Mescal (1.8%) and Harris Dickinson (0.7%). All three were fixtures of the speculative shortlists and all three opened this market in the mid-20s or higher, with Elordi briefly above 44% in early June. All three have since collapsed to low single digits. The pattern is consistent with traders treating them as names that were always going to appear on speculative lists because they are high-profile actors of the right age, rather than names with specific reporting behind them.

Theo James at 1.1% and the long tail. ScreenRant's September roundup described James as having faded from contention and Henry Cavill (0.8%), Tom Hardy (0.3%) and Idris Elba as effectively ruled out largely on age grounds. Aaron Taylor-Johnson (0.6%), heavily rumoured in 2024, now trades as a long shot. Below that, contracts on names such as James Norton, Tom Holland, Jonathan Bailey, Nicholas Galitzine, Richard Madden, Timothee Chalamet, Michael B Jordan, Tom Blyth, Robert James-Collier and even Pierce Brosnan sit at 0.1-0.3%, mostly with no bids at all.

Where is the value? On the reporting record, two contracts look most defensible to argue about. "No Bond chosen" at 24.4% is the cleanest expression of a view on timing, and it does not require picking an actor. Turner at 13.3% is the cheapest of the names with a history of serious reporting, though that reporting is older and his recent price action has been noisy rather than directional. For a single-name long shot, a contract like Barton at 4.7% would return roughly 600% on margin at 4x before costs if it merely returned to its September level near 12%, which is the kind of asymmetry this board offers, but the thin books on every name outside the top three mean entry and exit costs can be large relative to the price. Conversely, Lowden at 37.8% is the most liquid contract but carries the heaviest burden of proof: it needs both the right actor and a 2026 announcement.

Catalysts and windows to watch

Screen tests. The most important near-term input. Deadline reported over the summer that audition rounds were under way, with screen tests initially expected in August. Later reporting, including Belloni's, said they would slip to later in the fall. Any credible report that screen tests have been completed, or which actors attended them, would likely be the single biggest repricing event before an announcement.

Trade-press scoops. Deadline, Variety and Puck have broken most of the verifiable steps in this search (the audition rounds, the Francis audition, the test deals). A specific report from one of these outlets naming a finalist would carry far more weight than the podcast and interview remarks that drove the September spike. By contrast, tabloid reports have a mixed record in this cycle: the January claim that Turner was confirmed came to nothing, and the August Page Six report on Barton produced a price spike that later faded.

Press-tour remarks. The Lowden spike shows that an offhand comment from someone adjacent to the production can move the board by 20 points in a day. Slow Horses, the Spider-Man and Dune press cycles, and any appearances by Pascal, Heyman, Villeneuve or Knight are windows where a remark can reprice contracts, in either direction.

The December window. Pascal's end-of-year expectation is the only on-record timing guidance. If November passes without a credible report that screen tests are done, expect "No Bond chosen" to firm further and every actor contract to decay toward zero as the deadline approaches, since each one needs an announcement by December 31 to pay out.

The announcement itself. When it comes, it will settle the market almost instantly. Whoever is named goes to 100% and every other contract, including "No Bond chosen", goes to zero.

Bottom line

The next James Bond odds describe a two-stage race. On the question of who, Jack Lowden is the clear market favourite at 37.8%, built on the Osman podcast and Gary Oldman's later-qualified remarks rather than any official signal, with Callum Turner at 13.3% the only other name above 5%. On the question of when, the market puts about a one-in-four chance on no announcement at all before 2027, and that number has held steady for two months even as the actor contracts have swung around it.

My read: the board is roughly fair at the top, with Lowden's price reflecting real momentum but no hard confirmation, and the "No Bond chosen" contract is the one most likely to move in a straight line from here. If credible screen-test reporting arrives in October or November, it should compress "No Bond chosen" and concentrate probability on whichever names are reported as finalists; if it doesn't, the timing contract should keep rising as December approaches. A leveraged position on this market is best sized as a bet on that catalyst path, either on the timing contract or on a single name you think the next credible report will confirm, with margin set aside for the thin order books outside the top three.

Trade with up to 4x leverage: predmart.com/event/next-james-bond-actor-398

Related